New hope for hard-to-treat hepatitis c: experimental combo shows promise in phase 3 trial
NCT ID NCT00781274
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested a new drug called MP-424 combined with two standard medicines (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 weeks after treatment ended. The trial has been completed, and results may help improve options for people with this difficult-to-treat form of hepatitis C.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
Explore the condition pages connected to this study.